TO candidatesAs I said before, an offer from TPG would make a lot of sense. They already own Par Pharmaceuticals which is a generic drug company. CXR would add a strong investment to their portfolio, IMO.
https://www.tpg.com/industries/healthcare
https://www.parpharm.com/generics.php
Some reading:
https://www.theglobeandmail.com/globe-investor/investment-ideas/biotech-stock-swoon-sparks-buyout-interest-janus-manager/article29858926/